NCT05491213Active, not recruiting

TELESCOPE- TELEhealth Shared Decision-making COaching

TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary carE (TELESCOPE)

Source: ClinicalTrials.gov · Last updated 14 Oct 2026

Brief summary (registry, in English)

Hypothesis 1a: The investigators anticipate that navigator decision coaching, compared to enhanced usual care (EUC) will result in higher quality SDM for lung cancer screening (LCS )(primary outcome), greater knowledge of lung cancer screening benefits and harms, and lower decisional conflict. Hypothesis 1b: Compared to enhanced usual care (EUC), we expect that TELESCOPE will result in more screening discussions, increased initial for lung cancer screening (LCS) with low-dose CT scan (LDCT) uptake among interested participants, increased adherence to repeat LCS and diagnostic testing, and increased smoking cessation referrals for current smokers. Hypothesis 2: The investigators expect that a "booster" coaching session will increase adherence to repeat lung cancer screening (LCS).

Status (registry): Active, not recruiting
Study type: Interventional
Enrollment: 594 (estimated)
First submitted: 4 Aug 2022
Start date: 14 Feb 2023
Primary completion date: 2 Apr 2026
Lead sponsor: Rutgers, The State University of New Jersey
Diseases: Lung cancer
NCT number: NCT05491213

What you commit to

Study type: Interventional
Planned participants: 594
From 14 Feb 2023 to the primary completion date, 2 Apr 2026
2 sites in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

Have a history lung cancer
Were screened for lung cancer within the past 12 months
Have health conditions that make them poor candidates for curative treatment as determined by the primary care provider

Other

\- Cluster Randomized Trial
Excluded will be patients who:
Do not speak English
Are unable to provide informed consent Interviews (N=50)
- Providers/administrators will be excluded if they:
Are unable to provide informed consent Online surveys (N=130)
Are unable to provide informed consent
Women who are pregnant. English proficiency is required for the completion of surveys, and the intervention will be conducted in English.

Who the study is looking for

\- Inclusion Criteria Cluster Randomized Trial
Eligibility of patients for the cluster randomized trial will follow United States Preventive Services Task Force criteria for lung cancer screening. Specifically, patients must:
Be 50 to 77 years of age
Be a current or former smoker having quit within the past 15 years
Have at least a 20 pack-year smoking history
Be scheduled for a non-acute care visit at one of the study sites. Interviews (N=50)
- Participants completing the semi-structured interviews will be:
A practicing primary care clinician or a clinic director (n=20), nursing director, or clinic practice administrator (n=20) at one of the participating sites or a TELESCOPE study patient navigator (n=7) and nurse navigator (n = 3)
Age 18 or older
Fluent in English Online surveys (N=130)
- Providers completing online PRISM construct surveys will be:
A practicing primary care provider at one of the participating sites or a TELESCOPE study navigator
Age 18 or older
Fluent in English

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
The University of Texas MD Anderson Cancer Center Coordinator of this site? Confirm its status	Houston	United States	Unknown status
Rutgers Cancer Institute Coordinator of this site? Confirm its status	New Brunswick	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.